Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI) LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to mediate organ inflammation in the lungs, liver and kidneys There are currently no treatments available to prevent or treat AKI TORONTO, June 27, 2023 (GLOBE NEWSWIRE) — … Read more
April 18, 2023 07:10 ET | Source: Arch Biopartners TORONTO, April 18, 2023 (GLOBE NEWSWIRE) — Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that it has safely increased the maximum daily dose of … Read more
March 23, 2023 07:00 ET | Source: Arch Biopartners TORONTO, March 23, 2023 (GLOBE NEWSWIRE) — Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that Arch is receiving advisory services and up to $4,000,000 … Read more
February 07, 2023 07:05 ET | Source: Arch Biopartners TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) — Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, announced that an Arch scientist at the University … Read more
December 15, 2022 09:49 ET | Source: Arch Biopartners TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $201,459 in interest accrued up to September 30, 2022 … Read more
October 05, 2022 07:20 ET | Source: Arch Biopartners TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) — Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, welcomed Mr. Farris Smith of Novo Nordisk Canada … Read more
August 05, 2022 07:30 ET | Source: Arch Biopartners TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic Advisor for … Read more
TORONTO, Feb. 24, 2022 — Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that it has been named to the 2022 TMX Venture 50 List of Top Performing TSX Venture Exchange … Read more
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications, including moderate to severe cases of COVID-19, regardless of variant type. TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: … Read more
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $424,767.07 in interest accrued up to December 31, 2021 on all five of the deferred convertible notes outstanding … Read more